Cardiology Medical News about cardiovascular disease in type 2 diabetes;omega-3 treatment

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death

3. The Job Market for 2008-2009: Compensation

4. Renal Artery Stenosis

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes
Current Opinion in Lipidology, 01/09/09

Hartweg J et al. – A systematic review and meta-analysis confirms triglyceride lowering effects of omega-3 polyunsaturated fatty acids (PUFAs) and shows potential dose-response effects and improvements in thrombogenesis. Omega-3 PUFAs raise LDL levels without concomitant changes in lipid particle size. Changes in conventional risk factors are insufficient to explain the cardiovascular disease risk reductions proposed with omega-3 PUFAs.

Methods

Hypothesis-generating systematic review of the impact of marine-derived omega-3 PUFAs on lipid, glycemic, and hematologic risk factors in type 2 diabetes
Review of pooled data from randomized controlled trials to 20 September 2008
Pooled data: 7 new trials in 2007/2008 from 206 abstracts for total of 24 trials 1966-2008 of 1533 subjects

Results

Mean omega-3 PUFAs treatment dose and duration in new trials: 2.4 g/day for 24 wks
Compared with placebo, omega-3 PUFAs supplementation decreased triglycerides by 7%, fibrinogen by 10%, ADP platelet aggregation to ADP by 22%, and to collagen by 21%, with an LDL-cholesterol increase of 3%
None of following risk factors appeared beneficially influenced: HDL-cholesterol, LDL particle size, glycemia, insulinemia, inflammatory biomarkers, blood pressure
Few trial pts for some risk factors (such as inflammtory biomarkers)
Higher doses of omega-3 PUFAs (≥2 g/day) may have greater triglyceride-lowering effects

<< Previous
Catheter ablation for patients with ventricular fibrillation.

Next >>
ECG manifestations of left atrial flutter